Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Denosumab for Smoldering Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03839459
Recruitment Status : Recruiting
First Posted : February 15, 2019
Last Update Posted : July 8, 2021
Information provided by (Responsible Party):
Brea Lipe, University of Rochester

Brief Summary:
This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.

Condition or disease Intervention/treatment Phase
Smoldering Multiple Myeloma Drug: Denosumab Phase 2

Detailed Description:

This is an open label, Phase II trial of denosumab 120mg subcutaneous (SC) for patients with smoldering multiple myeloma (SMM). Subjects will be recruited from the James P. Wilmot Cancer Center, University of Rochester in Rochester, New York. Patients seen in the inpatient or outpatient setting with histologically confirmed SMM will be evaluated for this study.

20 patients will be treated as follows: Denosumab: day 1 = 120mg SC every 4 weeks for 12 cycles. Cycles will be 28 days in length. Patients will be followed after completion of the study per standard of care for progression free survival for an additional 2 years after the last dose of denosumab. All patients will take daily vitamin D and calcium supplements of at least 1200mg elemental calcium and 800IU of vitamin D unless documented hypercalcemia develops on study. Pre-existing hypocalcemia must be corrected prior to initiating therapy with denosumab. Serum vitamin D levels will be checked during screening and should be repleted to a total 25-hydroxyvitamin D level ≥30ng/mL.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Denosumab for Smoldering Multiple Myeloma
Actual Study Start Date : April 19, 2019
Estimated Primary Completion Date : June 1, 2022
Estimated Study Completion Date : June 1, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
Drug Information available for: Denosumab

Arm Intervention/treatment
Experimental: Denosumab Drug: Denosumab
120mg of Denosumab will be administered subcutaneously once every 4 weeks

Primary Outcome Measures :
  1. Proportion of subjects with a downgraded risk of progression of smoldering multiple myeloma if the risk category decreases. [ Time Frame: 1 year ]

    Risk Categories:

    Low Risk:Patient has SMM, but none of the listed risk factors Low-Intermediate Risk: 1 risk factor is present High-Intermediate Risk: 2 risk factors are present High Risk: 3 risk factors are present

    Risk Factors:

    1. BM plasma cell % ≥50
    2. M-protein ≥ 3g/dL
    3. Involved/ un-involved free light chains ≥ 8

Secondary Outcome Measures :
  1. Proportion of subjects with Skeletal related Events [ Time Frame: 1 year ]
    To be determined by the investigator

  2. Proportion of subjects with disease progression to Multiple Myeloma [ Time Frame: 1 year ]

    Risk Categories:

    Low Risk:Patient has SMM, but none of the listed risk factors Low-Intermediate Risk: 1 risk factor is present High-Intermediate Risk: 2 risk factors are present High Risk: 3 risk factors are present

    Risk Factors:

    1. BM plasma cell % ≥50
    2. M-protein ≥ 3g/dL
    3. Involved/ un-involved free light chains ≥ 8

  3. Proportion of subjects with progression free survival [ Time Frame: 3 year ]
    time to progression or death from any cause, whichever occurs first.

  4. Proportion of subjects with change in bone mineral density [ Time Frame: 1 year ]
    baseline and each post-treatment point

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient has confirmed SMM according to the definition of the International Myeloma Working Group (IMWG) definition: serum M-protein ≥3 g/dL or BMPC >10% but less than 60%, or both, along with normal organ and marrow function (CRAB) within 4 weeks prior to baseline. C: Absence of hypercalcemia, evidenced by a calcium ≤11 mg/dL. R: Absence of renal failure, evidenced by a creatinine ≤ 2.0mg/dL A: Absence of anemia, evidenced by a hemoglobin ≥10 g/dL.

    B: Absence of lytic bone lesions per IMWG recommendations:

    One of either PET-CT, low-dose whole-body CT (LDWBCT) or MRI of the whole body or spine. Increased uptake on PET-CT alone is not adequate for the diagnosis of multiple myeloma; evidence of underlying osteolytic bone destruction is needed on the CT portion of the examination.

  2. One of the risk factors below that portends for an increased risk of progression to MM:

    • An abnormal free light chain ratio
    • M-spike ≥ 4 g/dL
    • ≥ 50% bone marrow plasma cells
    • Immunoparesis ≥ 20% less than the institutional normal standard of the uninvolved immunoglobulins
  3. Serum calcium or albumin-adjusted serum calcium ≥ 2.1 mmol/L (8.4 mg/dL) and ≤ 2.9mmol/L (11.5 mg/dL) (Reference range 8.5-10.8 mg/dL)
  4. Able to tolerate daily supplementation of calcium and vitamin D
  5. Must have a vitamin D level ≥ 30 ng/mL after repletion
  6. Participants must have normal organ as defined below:

    • Total bilirubin ≤ 2.0 x institutional upper limit of normal (ULN); patients diagnosed with Gilbert's syndrome can enroll with a total bilirubin > 2 after review of the principal investigator
    • AST(SGOT) ≤2.5 × institutional ULN
    • ALT(SGPT) ≤2.5 × institutional ULN
  7. Age ≥ 18 years.
  8. ECOG PS ≤1
  9. Life expectancy greater than 12 months
  10. Subjects with reproductive potential must be willing to use, in combination with his/her partner, 2 highly effective methods of effective contraception or practice sexual abstinence throughout the study and continue for 5 months after the study duration. Subjects who are surgically sterile (e.g. history of bilateral tubal ligation, hysterectomy) or whose sexual partner is sterile (e.g. history of vasectomy) are not required to use additional contraceptive measures.
  11. Ability to understand and the willingness to sign a written informed consent document.

    -Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

  12. Statement on Inclusion of Women and Minorities - Men and women of all ethnicities and racial backgrounds are eligible for this study.

Exclusion Criteria:

  1. Prior administration of denosumab.
  2. Any history of IV bisphosphonate use prior to or during the study
  3. Prescription oral fluorides or bisphosphonate usage > 3 months within the past 2 years
  4. Systemic corticosteroids > 10mg prednisone per day
  5. Known secondary cause for osteopenia or osteoporosis
  6. Patient has symptomatic MM, as defined by any of the following:

    • Lytic lesions or pathologic fractures.
    • Anemia (hemoglobin <10 g/dL)
    • Hypercalcemia (corrected serum calcium > 11.0 mg/dL)
    • Renal insufficiency (creatinine > 2.0 mg/dL).
    • Clonal bone marrow plasma cells > 60%
    • An involved serum free light chain (kappa or Lambda) > 100mg/L with the ratio of the involved/uninvolved free light chains also > 100 mg/L
    • One or more osteolytic lesions on radiography, but more than one lesion is required if < 10% marrow plasma cells. From MRI imaging, there must be more than one lesion of > 5mm in size.
  7. Other: symptomatic hyperviscosity, amyloidosis, plasma cell leukemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein)
  8. Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw.
  9. Active dental or jaw condition that requires oral surgery, including tooth extraction.
  10. Non-healed dental/oral surgery, including tooth extraction.
  11. Planned invasive dental procedures during the course of study.
  12. Evidence of any of the following conditions per subject self-report or medical chart review:

    • Any prior invasive malignancy within 3 years of enrollment that may affect outcome of study
    • Any non-invasive malignancy not treated with curative intent or with known active disease within 3 years before enrollment that may affect outcome of study
    • Major surgery or significant traumatic injury occurring within 4 weeks before enrollment
    • Active infection with Hepatitis B virus or Hepatitis C virus
    • Known infection with human immunodeficiency virus (HIV) requiring IV anti-infective therapy
  13. Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment.
  14. Female subject of child-bearing potential is not willing to use, in combination with her partner, 2 methods of highly effective contraception during treatment and for 5 months after the end of treatment.
  15. Clinically significant hypersensitivity to denosumab or any components of denosumab 120mg.
  16. Known sensitivity to any of the products to be administered during the study (e.g., calcium, or vitamin D).
  17. Subject is receiving or is less than 14 days since ending other experimental drug (no marketing authorization for any indication).
  18. Any major medical or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03839459

Layout table for location contacts
Contact: Brea Lipe 585-275-4401

Layout table for location information
United States, New York
University of Rochester Recruiting
Rochester, New York, United States, 14642
Contact: Robin Boerman    585-273-1507      
Sponsors and Collaborators
University of Rochester
Layout table for investigator information
Principal Investigator: Brea Lipe University of Rochester Wilmot Cancer Center
Layout table for additonal information
Responsible Party: Brea Lipe, Associate Professor - Department of Medicine , Hematology/Oncology, University of Rochester Identifier: NCT03839459    
Other Study ID Numbers: UMMY18121
First Posted: February 15, 2019    Key Record Dates
Last Update Posted: July 8, 2021
Last Verified: July 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Brea Lipe, University of Rochester:
Smoldering Multiple Myeloma
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Smoldering Multiple Myeloma
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Precancerous Conditions
Bone Density Conservation Agents
Physiological Effects of Drugs